Sividon Diagnostics→Myriad Genetics
Acquisition · Cash · MYGN · announced May 31, 2016
Announced
May 31, 2016
Closed
May 31, 2016
Economics
Cash()
Pre-deal · pre-deal mark: 2016, year precision · Myriad Genetics press release — Sividon Diagnostics acquisition, 2016
€35M upfront + up to €15M performance milestones (~$56M total potential)
Target
Sividon Diagnostics
Breast Health · Diagnostic / genomic
HQ Cologne, Germany · Founded 2010
EndoPredict breast cancer prognostic test — 12-gene RNA expression assay evaluating breast cancer aggressiveness; spun out of Siemens Healthcare Diagnostics
- Globe Newswire — Myriad Genetics press release (May 31, 2016)
- SEC EDGAR — Myriad Genetics 8-K (May 31, 2016)
- GEN News — deal coverage (May 31, 2016)
Acquirer
Myriad Genetics (MYGN)
Diagnostics
HQ Salt Lake City, UT
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
EndoPredict 12-gene breast cancer prognostic test — foundational product for Myriad's international kit-based strategy; CE Marked in Europe, enables global oncology distribution expansion
Evidence ladder
Secondary (press / IR)
Globe Newswire — Myriad Genetics press release (May 31, 2016)
Primary (regulatory / filing)
SEC EDGAR — Myriad 8-K
SEC EDGAR filings (ticker locator)Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/899923/000119312516608366/d195219d8k.htm
Open source
Limitations
- €35M upfront + up to €15M performance milestones (~$56M total potential)
- Pre-deal valuation sourced from: Myriad Genetics press release — Sividon Diagnostics acquisition, 2016. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Breast Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Faxitron Bioptics | Hologic | Jul 31, 2018 | same evidence class | |
| SuperSonic Imagine | Hologic | Jun 21, 2019 | same evidence class | |
| Focal Therapeutics | Hologic | Sep 26, 2018 | value band |
Other verified deals by Myriad Genetics
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Gateway Genomics | Myriad Genetics | Nov 1, 2022 | Diagnostics | |
| Counsyl | Myriad Genetics | May 28, 2018 | Diagnostics |
Patient empowerment context
Empowerment context — Sividon Diagnostics
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should) (Company / product site)37%cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Company / product site)54%cited HLTH 2022Mapping source →
- Not aware of survivorship resources (Company / product site)2 in 3cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Foundation Medicine
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.